ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.556,31
-0,48%
S&P 500
5.354,93
0,04%
Dow Jones
38.942,70
0,15%
Euro vs US Dollar
1,08078
-0,77%
Bitcoin
70.912,02
0,21%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Solid Biosciences Inc (SLDB)

  7. Solid Biosciences Inc (SLDB) News

SLDB

Solid Biosciences (SLDB)

Solid Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SLDB
DatumZeitQuelleÜberschriftSymbolFirma
04/06/202422h00GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
20/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
15/05/202414h26Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SLDBSolid Biosciences Inc
15/05/202413h52GlobeNewswire Inc.Solid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
15/05/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLDBSolid Biosciences Inc
07/05/202413h00GlobeNewswire Inc.Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:SLDBSolid Biosciences Inc
07/05/202400h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
02/05/202422h05GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
03/04/202422h05GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
01/04/202413h45GlobeNewswire Inc.Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
27/03/202412h00GlobeNewswire Inc.Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumNASDAQ:SLDBSolid Biosciences Inc
13/03/202412h44GlobeNewswire Inc.Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
07/03/202413h00GlobeNewswire Inc.Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDNASDAQ:SLDBSolid Biosciences Inc
06/03/202414h00GlobeNewswire Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesNASDAQ:SLDBSolid Biosciences Inc
16/02/202418h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202417h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202417h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202417h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202417h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/02/202416h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
09/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
30/01/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
30/01/202422h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLDBSolid Biosciences Inc
20/01/202401h23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/01/202414h50Dow Jones NewsSolid Biosciences Gets Orphan Drug Designation for SGT-003NASDAQ:SLDBSolid Biosciences Inc
16/01/202414h00GlobeNewswire Inc.Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
12/01/202423h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
11/01/202423h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
10/01/202422h31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
08/01/202413h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLDBSolid Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SLDB

Kürzlich von Ihnen besucht

NASDAQ
TSLA
Tesla
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
TG
CBK
Commerzbank
FX
EURJPY
Euro vs Yen
TG
RHM
Rheinmetall
TG
432
Arbor Metals
TG
BAYN
Bayer
TG
TUI1
Tui
TG
DBK
Deutsche Bank
NYSE
NKE
Nike
USOTC
BASFY
BASF (QX)
TG
BAS
BASF
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten